Welcome to our dedicated page for Anika Therapeutics news (Ticker: ANIK), a resource for investors and traders seeking the latest updates and insights on Anika Therapeutics stock.
Anika Therapeutics, Inc. (NASDAQ: ANIK) is a global joint preservation company focused on early intervention orthopedics, osteoarthritis (OA) pain management, and regenerative solutions based on hyaluronic acid and implant technologies. This news page aggregates company-issued updates and market-moving announcements so readers can follow how Anika’s clinical programs, product portfolio, and financial performance evolve over time.
News about Anika commonly covers quarterly and annual financial results, including performance in its Commercial Channel and OEM Channel, as well as commentary on operating expenses, cost-saving measures, and capital allocation decisions such as share repurchase programs. Investors can also find updates on governance and compensation topics, including amendments to equity incentive plans and inducement grants made under Nasdaq Listing Rule 5635(c)(4).
A significant portion of Anika’s news flow focuses on clinical and regulatory milestones for its key products. Examples include updates on the U.S. pivotal Phase III FastTRACK study for the Hyalofast cartilage repair scaffold, the filing of the third and final PMA module for Hyalofast with the U.S. Food and Drug Administration, and progress toward a U.S. New Drug Application for Cingal, the company’s non-opioid, single-injection OA pain management product. Releases also describe commercial milestones, such as Cingal surpassing one million injections worldwide and the growth trajectory of the Integrity Implant System.
Corporate and leadership developments are another recurring theme. Anika issues press releases on planned leadership transitions, board changes, and strategic refocusing around its hyaluronic acid portfolio and regenerative solutions. By reviewing the ANIK news stream on this page, readers can monitor how clinical data, regulatory submissions, commercial performance, and governance actions shape the company’s position in osteoarthritis pain management and orthopedic regenerative medicine.
Anika Therapeutics (NASDAQ: ANIK) has launched its WristMotion® Total Wrist Arthroplasty (TWA) System at the ASSH 2021 annual meeting, aimed at treating wrist arthritis. This innovative system enhances carpal stability and allows for natural wrist motions, offering an alternative to traditional wrist fusion methods. Early clinical feedback has been positive, with over 2,600 cases of related systems performed since 2015. The TWA System is designed in collaboration with leading surgeons and aims to restore wrist function and improve patient mobility.
Anika Therapeutics (NASDAQ: ANIK) has received 510(k) clearance from the FDA for its Tactoset® Injectable Bone Substitute. This clearance allows Tactoset to augment hardware and support bone fragments during surgical procedures. With this expanded indication, the addressable market now includes augmentation of suture anchor fixation, a significant growth area for Anika. Tactoset, launched in Q4 2019, is a calcium phosphate-based biocompatible bone graft that enhances surgical outcomes. Anika plans to actively market this indication starting in October 2021.
Anika Therapeutics (NASDAQ: ANIK) announced their participation in the Morgan Stanley 19th Annual Global Healthcare Conference, taking place virtually on September 15, 2021, at 2:00 p.m. ET. Dr. Cheryl Blanchard, CEO, and Michael Levitz, CFO, will engage in a fireside chat. Investors can listen to the live audio webcast on Anika’s website under the Investor Relations section, with an archive available later. Anika focuses on early intervention orthopedics, creating minimally invasive products to enhance patient active living.
Anika Therapeutics (NASDAQ: ANIK) will showcase its complete joint preservation and restoration portfolio at the 2021 AAOS Annual Meeting in San Diego, California, from September 1-3. The company, now integrated with Arthrosurface and Parcus Medical, aims to lead in early intervention orthopedics. Featured products include the OVOMotion Total Shoulder System and Tactoset Injectable Bone Substitute. Notably, the OVOMotion system shows no loosening after 4,000 cycles. Anika's focus on innovative solutions addresses unmet needs in orthopedic care.
Anika Therapeutics reported a 24% year-over-year revenue growth for Q2 2021, totaling $38.1 million, recovering from earlier COVID impacts. Joint Preservation and Restoration revenue surged 79% to $11.9 million, while Joint Pain Management grew 9% to $24.3 million. The company expects full-year revenue growth of 11-14%, up from prior guidance. Net income improved to $6.5 million or $0.45 per diluted share, aided by a $9.8 million reduction in contingent consideration. Despite these gains, uncertainty due to the COVID pandemic remains a headwind.
On July 19, 2021, Anika Therapeutics (NASDAQ: ANIK) announced plans to issue its Q2 2021 financial results after market close on August 5, 2021. An investor conference call is scheduled for the same day at 5:00 p.m. ET to discuss the results and business highlights. The call will be accessible via toll-free and international numbers, and will also be available through a live audio webcast on Anika's Investor Relations website. Anika is focused on early intervention in orthopedics, providing minimally invasive solutions for joint preservation.
Anika Therapeutics (NASDAQ: ANIK) has initiated a limited launch of its WristMotion Total Wrist Arthroplasty (TWA) System, aimed at alleviating pain and restoring motion in arthritic wrist joints. The first surgery was performed on June 30, 2021, by Dr. Arnold-Peter C. Weiss at University Orthopedics, Rhode Island. The system, which received FDA clearance in October 2020, replaces both the radial and carpal sides of the wrist joint. The limited launch will progress to a full nationwide launch in Fall 2021, with presentations at major orthopedic meetings.
Anika Therapeutics (NASDAQ: ANIK) held its 2021 Virtual Investor Day, outlining a multi-year Joint Preservation strategy aimed at accelerating revenue growth and enhancing profitability. The company raised its 2021 revenue growth forecast to 10%-13% and reiterated a target to double 2019 revenues to approximately $230 million by 2024, focusing on the joint preservation market, valued at over $8 billion. Anika's leadership emphasized leveraging HA-based technologies and expanding its commercial presence to achieve these goals while navigating delays in pivotal trials due to COVID-19.
Anika Therapeutics, a global joint preservation company, will host its 2021 Virtual Investor Day on June 3, 2021, starting at 9:00 AM EDT. Key executives, including President Cheryl Blanchard and CFO Mike Levitz, will present an overview of the company's business strategy, product portfolio, R&D pipeline, and financial objectives. The event will feature presentations followed by a Q&A session with senior leaders. A webcast will be available on the company’s Investor Relations website for replay.
Anika Therapeutics reported Q1 2021 revenue of $34.3 million, down 3% year-over-year. Joint Preservation revenue surged 55% to $12.2 million, driven by acquisitions, while Joint Pain Management dropped 24% to $19.3 million, mainly due to COVID impacts. The company's revenue mix is shifting positively, with Joint Preservation now 36% of total revenue. Net income fell to $2.8 million ($0.20 per share) versus $5.8 million ($0.40 per share) last year. For 2021, Anika expects upper 20% to low 30% growth in Joint Preservation, projecting overall revenue growth in the high single to low double digits.